Optiject (Ioversol)

Ioversol’s multiple iodine atoms absorb X‑ray photons strongly. After intravenous injection, the iodine distributes in the vascular and extracellular spaces, raising the attenuation of those areas on radiographic images. This creates a contrast difference between structures, allowing detailed visualization of vessels, organs, and lesions.

The dose of Optiject is determined by the prescribing clinician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. Healthcare professionals calculate the appropriate volume at the point of care.

Optiject should be used in pregnancy only when the diagnostic benefit outweighs potential fetal risk, as iodinated contrast crosses the placenta. It is excreted in breast milk; breastfeeding mothers should discuss risks with their physician, who may advise temporary cessation of nursing.

To order Optiject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Optiject (ioversol) is a non‑ionic, low‑osmolality contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents, its iodine concentration and viscosity are similar, providing comparable image quality while reducing the incidence of adverse reactions.

Optiject should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze; allow the solution to reach room temperature before use if it has been refrigerated during transport.

Optiject is administered intravenously by a trained healthcare professional. The solution is injected through a peripheral or central venous line, typically as a rapid bolus or power‑injector delivery, depending on the imaging protocol and equipment used.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and rare cardiovascular events like hypotension or arrhythmias. Immediate medical attention is required if any of these reactions occur.

Optiject is contraindicated in patients with a known hypersensitivity to ioversol or any iodinated contrast media, those with uncontrolled hyperthyroidism, and individuals with severe renal dysfunction where alternative imaging methods are available. Clinicians should evaluate each patient’s risk factors before administration.